Your session is about to expire
← Back to Search
Ibrutinib + Rituximab for Graft-versus-Host Disease
Study Summary
This trial is testing a new treatment for GVHD made up of Ibrutinib and Rituximab. 35 patients will be enrolled and monitored for 12 months to see how effective and safe the treatment is.
- Graft-versus-Host Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 201 Patients • NCT03053440Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are unable to take medicine by mouth.
- Group 1: Rituximab + Ibrutinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any remaining openings in this clinical experiment for participants?
"Affirmative. Clinicaltrials.gov presents evidence that this study is now recruiting its participants, the protocol having been posted on December 16th 2019 and revised October 19th 2022. 35 individuals are necessary to be enrolled from one facility."
What can you tell me about past experiments regarding Ibrutinib?
"Presently, 521 studies on ibrutinib remain active with 105 of them being in the third phase. While most are conducted near Ascoli Piceno, Provincia, there exists a total of 18455 trial sites across the world."
What is the sample size for this experiment?
"Indeed, the information found on clinicaltrials.gov demonstrates that this study is actively enrolling participants. The trial was initially posted in December 16th 2019 and was last amended on October 19th 2022. 35 patients are needed across a single site for successful recruitment."
To what extent can Ibrutinib be detrimental to a person's health?
"Our team has concluded that Ibrutinib's safety is of a moderate level, as evidenced by the score of 2. This corresponds with Phase 2 trials, where evidence for efficacy is lacking but some data exists regarding its security profile."
Share this study with friends
Copy Link
Messenger